Frontlight ResearchEarly access
Not yet recruitingNo phase
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
Key facts
- Who runs it
- Implantica CE Reflux Ltd.
- Where
- Germany and Spain5 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 500 people, planned
- Started
- 15 Sept 2025
- Expected to end
- 1 Aug 2035
- Type of study
- Interventional
- Treatments tested
- RefluxStop™ implantation
- Record updated
- 4 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Willing and able to provide informed consent and to participate in the registry study
- Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older
- Documented GERD present for ≥ 6 months. Typical symptoms are defined as heartburn
- 24-hour pH or impedance pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be < 4 for ≥ 4.5% of total time during a 24-hour monitoring) and/or total reflux episodes >55 or weekly acid >26 for > 5 seconds, all measured 5 cm above LES)
- Suitable to undergo general anaesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator
Who cannot take part
- History of bariatric surgery wherein the stomach fundus has been extirpated
- Known sensitivity or allergies to silicone materials
- Subjects that are unable to comply with the registry requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement)
- Hiatal Hernia larger than 8 cm
- Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed. Patients with substantially weak peristalsis (manometry DCI value 100-200) in esophagus measured during manometry would continue the simplified contrast swallow x-ray to perform a simplified two-hour gastric emptying contrast swallow
- Female subjects who are pregnant
- Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry procedure (as outlined in the IFU)
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the treatment of subjects suffering from GERD.
Read full original descriptionShow less
Following surgery, patients will have follow-ups visits at 3 and 6 months and annually up to 7 years.
The group in the trial
- Single arm: interventionOther group
Single arm registry: all enrolled patients will be implanted with RefluxStopTM
Treatment: RefluxStop™ implantation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Post-market Registry Study Based on Standard Clinical Care to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice
- Record updated
- 4 June 2025